Chromocell Therapeutics Corp.(CHRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CHRO Chromocell Therapeutics Corp.

Market Closed 11-22 16:00:00 EST

0.6600

+0.0288

+4.56%

盘后0.6251

-0.0349-5.29%

17:54 EST

High0.6625	Low0.5966	Vol85.34K
Open0.6001	D1 Closing0.6312	Amplitude10.44%
Mkt Cap3.98M	Tradable Cap1.06M	Total Shares6.03M
T/O54.60K	T/O Rate5.32%	Tradable Shares1.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CHRO","market":"US","secType":"STK","nameCN":"Chromocell Therapeutics Corp.","latestPrice":0.66,"timestamp":1732309200000,"preClose":0.6312,"halted":0,"volume":85335,"hourTrading":{"tag":"盘后","latestPrice":0.6251,"preClose":0.66,"latestTime":"17:54 EST","volume":1400,"amount":875.14,"timestamp":1732316060710},"delay":0,"floatShares":1603899,"shares":6028011,"eps":-2.204187,"marketStatus":"Market Closed","change":0.0288,"latestTime":"11-22 16:00:00 EST","open":0.6001,"high":0.6625,"low":0.5966,"amount":54596.496716999995,"amplitude":0.104404,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.204187,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":0.6312,"postHourTrading":{"tag":"盘后","latestPrice":0.6251,"preClose":0.66,"latestTime":"17:54 EST","volume":1400,"amount":875.14,"timestamp":1732316060710},"volumeRatio":2.339992547585928},"requestUrl":"/m/hq/s/CHRO/tweets","defaultTab":"tweets","newsList":[{"id":"2485418787","title":"Chromocell changes name to Channel Therapeutics, provides program updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2485418787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485418787?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:55","pubTimestamp":1732200928,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics (CHRO) announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation, along with reincorp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/chromocell-changes-name-to-channel-therapeutics-provides-program-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/chromocell-changes-name-to-channel-therapeutics-provides-program-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","CHRO"],"gpt_icon":0},{"id":"2485884490","title":"Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2485884490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485884490?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:49","pubTimestamp":1732200547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8LLCYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2485749228","title":"Chromocell Therapeutics Rebrands to Focus on Pain Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2485749228","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485749228?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:28","pubTimestamp":1732199319,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics Corp ( ($CHRO) ) just unveiled an update. Channel Therapeutics Corporation, formerly Chromocell Therapeutics, has rebranded...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-rebrands-to-focus-on-pain-treatments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-rebrands-to-focus-on-pain-treatments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHRO","LENZ","BK4139"],"gpt_icon":0},{"id":"2484113691","title":"YY Group Holding Celebrates Hong Ye Group’s Wins for Excellence in Workplace and Cleaning Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484113691","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484113691?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:40","pubTimestamp":1732110000,"startTime":"0","endTime":"0","summary":"On November 15, Hong Ye Group was celebrated among Asia’s top employers at the HR Asia Best Companies to Work for in Asia 2024 awards ceremony at Marina Bay Sands, Singapore. Rachel Xu, Chief Human Resources Officer  of YY Group Holding Limited, proudly accepted the award on behalf of the company.Mike Fu, CEO of YY Group Holding Limited, expressed his gratitude for the recognition:\"We are thrilled to be named one of Asia's Best Companies to Work For. This achievement is a testament to our efforts in fostering a supportive and inclusive environment where every employee can thrive. We thank all our staff for their dedication and contributions, which have made this possible.\". Hong Ye Group, a subsidiary of YY Group Holding Limited, is renowned for its exceptional facility management services, catering to a wide range of sectors including hospitality, corporate, and healthcare. Known for its high standards and commitment to quality, Hong Ye Group continuously strives to enhance operationa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Tshu3P.F2DddUwTiSAWww--~B/aD00Njt3PTE1NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f49022a8eb9f0b69bef6b767d4275da0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Tshu3P.F2DddUwTiSAWww--~B/aD00Njt3PTE1NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f49022a8eb9f0b69bef6b767d4275da0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/yy-group-holding-celebrates-hong-134000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4503","BK4513","CFO","CHRO","BK4531","BK4585","BK4077","BK4535","BK4588","YY","BK4023","BK4551","BK4526","YYGH","BK4120","BK4139"],"gpt_icon":1},{"id":"2484098075","title":"Chromocell Therapeutics Merges into Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2484098075","media":"TIPRANKS","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484098075?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:27","pubTimestamp":1731968843,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics Corp ( ($CHRO) ) has provided an announcement. Chromocell Therapeutics Corporation has merged into its subsidiary, Channel ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-merges-into-channel-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-merges-into-channel-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHRO","BK4139","LENZ"],"gpt_icon":0},{"id":"2483713876","title":"Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483713876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483713876?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"– Clinical data from the RESET-Myositis and RESET-SLE trials, along with initial clinical data from the RESET-SSc trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 –。– 16 patients enrolled with 10 patientsdosed as of November 12 across the RESET clinical development program; 40 U.S. clinical sites actively recruiting patients –。– Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 –。– Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International –。PHILADELPHIA, Nov. 14, 2024  -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2024, and pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-reports-third-quarter-120000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CABA","CHRO","BK4139","ACR","BK4077","BK4110","CTA","SLE"],"gpt_icon":0},{"id":"2479709345","title":"Gildan Reports Record Third Quarter Revenue and Adjusted Diluted EPS¹ and Updates its Full Year 2024 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2479709345","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479709345?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:45","pubTimestamp":1730371500,"startTime":"0","endTime":"0","summary":"(all amounts are in U.S. dollars except where otherwise indicated) (1) Please refer to \"Definition and reconciliation of non-GAAP financial measures\" in this press release  Record third quarter net sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2972425/0/en/Gildan-Reports-Record-Third-Quarter-Revenue-and-Adjusted-Diluted-EPS-and-Updates-its-Full-Year-2024-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSU","CHRO","GSG","BK4139"],"gpt_icon":0},{"id":"2479255409","title":"FirstEnergy names Karen McClendon CHRO","url":"https://stock-news.laohu8.com/highlight/detail?id=2479255409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479255409?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:10","pubTimestamp":1730229015,"startTime":"0","endTime":"0","summary":"FirstEnergy (FE) announced that Karen McClendon has been named senior VP and chief human resources officer, or CHRO, effective November 11. McClend...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/firstenergy-names-karen-mcclendon-chro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/firstenergy-names-karen-mcclendon-chro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4081","CHRO","BK4585","FE","BK4588"],"gpt_icon":0},{"id":"2479253922","title":"Press Release: FirstEnergy Names Karen McClendon Senior Vice President and Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2479253922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479253922?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:00","pubTimestamp":1730228400,"startTime":"0","endTime":"0","summary":"AKRON, Ohio, Oct. 29, 2024 /PRNewswire/ -- FirstEnergy Corp.  announced today that Karen McClendon has been named Senior Vice President and Chief Human Resources Officer , effective Nov. 11.In this role, McClendon will spearhead efforts to integrate and advance the company's human capital strategy, ensuring alignment with the strategic vision to establish FirstEnergy as a premier electric company. She will oversee key human resources functions, including talent management, benefits and compensation, labor and employee relations, and the commitment to building an inclusive workforce and a workplace reflective of the communities served by FirstEnergy. McClendon will report to Brian Tierney, FirstEnergy President and Chief Executive Officer.McClendon joins FirstEnergy with more than three decades of human resources experience. She has a proven track record in developing solutions, delivering results, generating support across multiple levels, leading culture transformation and fostering a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGR.SI","CHRO","BK4139","BK6046","FE","BK4585","BK4588","BK4081"],"gpt_icon":0},{"id":"2479401331","title":"Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479401331","media":"THOMSON REUTERS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479401331?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:30","pubTimestamp":1730205000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA1ZG1WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","BK4139"],"gpt_icon":0},{"id":"2479404331","title":"Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479404331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479404331?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:30","pubTimestamp":1730205000,"startTime":"0","endTime":"0","summary":"FREEHOLD, N.J., Oct. 29, 2024  -- Chromocell Therapeutics Corporation , , a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company’s novel NaV1.7 molecule for treating chronic pain and eye pain.There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product.“We are leveraging our existing know-how and intellectual property to target different pain indications and methods of delivery in an efficient and synergistic manner. We are taking advantage of the extensive pre-clinical and Phase I studies performed with CC8464 demonstrating strong efficacy in a wide variety of preclinical models and no dose limiting tolerability conc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chromocell-announces-unveiling-injectable-depot-123000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHRO"],"gpt_icon":0},{"id":"2477463826","title":"Chromocell Announces Amendment to Stock Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2477463826","media":"THOMSON REUTERS","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477463826?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:45","pubTimestamp":1729773900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nTUACBWVR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","BK4139"],"gpt_icon":0},{"id":"2477635353","title":"Chromocell Announces Amendment to Stock Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2477635353","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477635353?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:45","pubTimestamp":1729773900,"startTime":"0","endTime":"0","summary":"FREEHOLD, N.J., Oct. 24, 2024  -- Chromocell Therapeutics Corporation , , a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors  has authorized an amendment  to the Company’s existing stock repurchase plan  to increase the total value of shares of Chromocell’s common stock  available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000.In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 2024 to June 30, 2025.The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sod","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chromocell-announces-amendment-stock-repurchase-124500441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHRO"],"gpt_icon":0},{"id":"2473173498","title":"Press Release: IFS strengthens Executive Board with CIO and CHRO appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2473173498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473173498?lang=en_us&edition=fundamental","pubTime":"2024-10-07 18:33","pubTimestamp":1728297180,"startTime":"0","endTime":"0","summary":"Helena Nimmo appointed CIO and Debra McCowan appointed CHRO to fuel IFS's next phase of growth in pioneering and dominating Industrial AI. LONDON, Oct. 7, 2024 /PRNewswire/ -- IFS, the leading provider of enterprise cloud and Industrial AI software, has made two senior appointments to its Executive Board. Helena Nimmo joins as global Chief Information Officer  and Debra McCowan as Chief Human Resources Officer .Nimmo joins from Endava, a US-listed global technology company with over 12,000 employees. As CIO at IFS, Nimmo will engage CIOs and tech leaders at IFS customers to help them with their strategic transformation journeys, as well as driving the effective application of technology within IFS to deliver better products and services to customers. With IFS leading the adoption of Industrial AI across the world, Nimmo will drive the integration of AI across the IFS community, enabling IFS customers to deliver exceptional moments of service to their clients.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","FSM","LU0300738605.USD","TM","IFS","BK4099","BK4139","BK4555","LU0300738514.USD","BK4588","CIO","SCM","BK4135","03160","BK4223","CHRO","BK4207","BK4194","BK4210"],"gpt_icon":0},{"id":"2470716738","title":"Press Release: SPX Technologies Announces Appointment of Jennifer Carpenter as Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2470716738","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470716738?lang=en_us&edition=fundamental","pubTime":"2024-09-26 20:30","pubTimestamp":1727353800,"startTime":"0","endTime":"0","summary":"CHARLOTTE, N.C., Sept. 26, 2024  -- SPX Technologies, Inc.  , is pleased to announce the appointment of Jennifer Carpenter as its new Chief Human Resources Officer , effective September 30, 2024. She succeeds Tausha White, who earlier this year announced her decision to retire. Ms. Carpenter joins SPX with an extensive background of human resources and leadership experience.Gene Lowe, President and CEO, commented, \"We are very pleased to welcome Jennifer to the SPX Technologies team. Her expertise at developing strong business partnerships, building talent and organizational capabilities and empowering employees is an excellent fit with SPX's growth initiatives. She has a strong track record of helping business leaders drive process efficiencies and successfully manage organic and inorganic growth.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRO","LU1815336091.USD","SPXC","IE0009354923.USD","LU0757428866.USD","BK4161","BK4139"],"gpt_icon":0},{"id":"2468464099","title":"Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2468464099","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468464099?lang=en_us&edition=fundamental","pubTime":"2024-09-20 20:35","pubTimestamp":1726835700,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 20, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held September 19th are now available for online viewing. This event was co-sponsored by Zacks Small-Cap Research.The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company’s resource section.Select companies are accepting 1x1 management meeting requests through September 24th.Virtual Investor Conferences  is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, the VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-123500670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","EVAX","TQQQ","BK4139","MNQmain","PSQ","UNCY","BK4179","BK4007","SQQQ","AEMD","QID","ACST","QLD","BVAXF","FET","PLX","ADAP","CHRO","NQmain","GENFF","VNRX","APRE"],"gpt_icon":1},{"id":"2468391719","title":"Press Release: Resolute Holdings Completes Acquisition of Majority Interest in CompoSecure","url":"https://stock-news.laohu8.com/highlight/detail?id=2468391719","media":"Dow Jones","labels":["Executive Changes","Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468391719?lang=en_us&edition=fundamental","pubTime":"2024-09-18 04:05","pubTimestamp":1726603500,"startTime":"0","endTime":"0","summary":"CompoSecure announces board changes with David Cote, former CEO of Honeywell, as executive chairman as well as the appointment of five new board members. NEW YORK and SOMERSET, N.J., Sept. 17, 2024  -- Resolute Holdings I, LP and its affiliated vehicles , an investment firm under the leadership of David Cote and Tom Knott, and CompoSecure, Inc.   today announced the closing of Resolute's acquisition of a majority interest in CompoSecure in accordance with the stock purchase agreements among Resolute and certain shareholders of CompoSecure. In conjunction with the closing, David Cote has been appointed executive chairman of the board of directors of CompoSecure and Tom Knott, Joseph DeAngelo, Roger Fradin, Mark James, and John Cote have also been appointed to the board of directors.Pursuant to the stock purchase agreements, the selling shareholders exchanged the entirety of their Class B units for Class A shares and Resolute has now acquired 49.3 million Class A shares, representing app","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes,Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRO","BK4550","BK4127","LU1668664300.SGD","IE00BMPRXR70.SGD","LU2237443549.SGD","BK4504","LU1988902786.USD","IE00BMPRXN33.USD","LU1093756325.SGD","IE00BFXG1179.USD","LU2237443622.USD","LU0106831901.USD","IE00B19Z3B42.SGD","LU2357125470.USD","LU1064131342.USD","IE00BMPRXQ63.HKD","LU0823414478.USD","LU2065731478.USD","LU2264538146.SGD","LU1791807156.HKD","LU2294711713.HKD","LU1093756168.USD","LU2506951792.HKD","IE0004086264.USD","IE0004091025.USD","LU2237443465.HKD","IE0034235188.USD","LU2237443895.HKD","BK4139","LU0823414551.USD","LU2237443978.SGD","LU2237438978.USD","IE00BSNM7G36.USD","LU0348723411.USD","IE00B19Z3581.USD","BK4585","BK4170","LU2237443382.USD","IE0002270589.USD","BK4552","VRT","BK4533","LU2249611893.SGD","CMPO","BK4588","BK4096"],"gpt_icon":1},{"id":"2468355862","title":"Press Release: Douglas Dynamics Announces Senior Management Team Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2468355862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468355862?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:58","pubTimestamp":1726574280,"startTime":"0","endTime":"0","summary":"Mark Van Genderen Promoted to Chief Operating Officer. Chief Human Resources Officer Linda Evans to Retire at Year-End. Shannan Vlieger Promoted to Senior Vice President, People and Culture. Linda Evans has informed the company of her plans to retire on January 2, 2025, after 16 years with the company. Linda joined the company in 2008 as Vice President of Human Resources. She was promoted to Executive Vice President of Human Resources in 2022, and Chief Human Resources Officer in 2023. During her tenure, the company has grown from approximately 500 employees in three locations to approximately 1,700 employees in 21 locations. Linda has played a pivotal role in numerous aspects of the company's growth including its initial public offering, the completion and integration of multiple acquisitions and developing initiatives to defi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4585","LU1992135472.HKD","BK4232","R","ESG","TISI","BK4120","LU1992135399.USD","BK4149","COO","GB00BDT5M118.USD","BK4022","PLOW","LU2272731782.SGD","BK4588","CHRO","LU2211815571.USD","LU2272731600.USD","BK4139"],"gpt_icon":0},{"id":"2468847137","title":"Life Sciences Virtual Investor Forum Agenda Announced for September 19th","url":"https://stock-news.laohu8.com/highlight/detail?id=2468847137","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468847137?lang=en_us&edition=fundamental","pubTime":"2024-09-17 00:07","pubTimestamp":1726502820,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 16, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held September 19th. This event is co-sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.“We’re looking forward to bringing the latest innovators together at the Life Sciences Virtual Investor Forum this Thursday,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “In collaboration with Zacks Small-Cap Research, this conference will provide an efficient platform for these companies to seamlessly engage their investor base.”Virtual Investor Conferences Contact:John ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-160700187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACST","VNRX","BK4179","SQQQ","UNCY","BK4590","BK4561","ADAP","BVAXF","TQQQ","BK4581","PLX","NQmain","BK4139","BK4588","BK4585","GENFF","QID","FET","EVAX","BK4144","CHRO","ET","APRE",".IXIC","QLD","MNQmain","AEMD","BCLI","PSQ"],"gpt_icon":1},{"id":"2467817970","title":"Chromocell to Participate in Life Sciences Investor Forum September 19th","url":"https://stock-news.laohu8.com/highlight/detail?id=2467817970","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467817970?lang=en_us&edition=fundamental","pubTime":"2024-09-16 20:35","pubTimestamp":1726490100,"startTime":"0","endTime":"0","summary":"This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chromocell-participate-life-sciences-investor-123500781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FET","CHRO","BK4139","BK4179"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chromocell.com","stockEarnings":[{"period":"1week","weight":0.046},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.2235},{"period":"6month","weight":-0.5398},{"period":"1year","weight":-0.89},{"period":"ytd","weight":-0.89}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.","exchange":"AMEX","name":"Chromocell Therapeutics Corp.","nameEN":"Chromocell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chromocell Therapeutics Corp.(CHRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Chromocell Therapeutics Corp.(CHRO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Chromocell Therapeutics Corp.,CHRO,Chromocell Therapeutics Corp.股票,Chromocell Therapeutics Corp.股票老虎,Chromocell Therapeutics Corp.股票老虎国际,Chromocell Therapeutics Corp.行情,Chromocell Therapeutics Corp.股票行情,Chromocell Therapeutics Corp.股价,Chromocell Therapeutics Corp.股市,Chromocell Therapeutics Corp.股票价格,Chromocell Therapeutics Corp.股票交易,Chromocell Therapeutics Corp.股票购买,Chromocell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chromocell Therapeutics Corp.(CHRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Chromocell Therapeutics Corp.(CHRO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}